MRSA Notes

Ceragenix Pharmaceuticals, Inc., a biopharmaceutical company focused on infectious disease and dermatology, announced that it has entered into a research and development agreement with an internationally recognized research laboratory to develop formulations, in the form of nasal ointments, designed to prevent influenza infection and to decolonize the nasal passage of methicillin-resistant staph aureus (MRSA). The nasal ointments will contain the Company’s CSA-13, a member of the class of proprietary Ceragenin(TM) compounds, which has been shown in in vitro testing to prevent influenza infection of epithelial cells and to be highly bactericidal against MRSA. Pending successful formulation, the Company plans on proceeding with further drug development activities.

MRSA is a form of staphylococcus that is now resistant to many antibiotics and represents nearly 70 percent of all staph infections found in hospital settings. Nasal ointments containing mupirocin are now commonly used to decolonize patients who carry MRSA in their nasal fluid, however there have been recent reports of increasing resistance to mupirocin. Studies suggest that prolonged and widespread use of mupirocin is associated with the development of resistance.

Source

Ceragenix, colonization, Infection Prevention Products, MRSA, Research and Development

Share This